



(51) International Patent Classification:

A61K 39/00 (2006.01) A61P 31/04 (2006.01)
A61K 47/68 (2017.01) A61P 31/12 (2006.01)
A61K 47/69 (2017.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/046728

(22) International Filing Date:

13 September 2024 (13.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/538,122 13 September 2023 (13.09.2023) US

(71) Applicant: TRUSTEES OF TUFTS COLLEGE
[US/US]; Ballou Hall, 4th Floor, Medford, MA 02155 (US).

(72) Inventors: XU, Qiaobing; 216 West Cummings Park,
Woburn, MA 01801 (US). ZHAO, Yu; Ballou Hall, 4th
Floor, Medford, MA 02155 (US).

(74) Agent: GORDON, Dana, M. et al.; Foley Hoag LLP, 155
Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,


AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PROTEOLYSIS-TARGETING CHIMERA TUMOR VACCINE

FIG. 1



(57) Abstract: Disclosed are compounds comprising an active agent covalently linked to a tumor antigen. Also disclosed herein nanoparticles comprising a tumor antigen covalently linked to an active agent and a plurality of lipid or lipidoids.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*